- Home
- ABLV vs QNCX Comparison
ABLV vs QNCX Comparison
Compare ABLV & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABLV
- QNCX
- Stock Information
- Founded
- ABLV 2015
- QNCX 2012
- Country
- ABLV China
- QNCX United States
- Employees
- ABLV N/A
- QNCX N/A
- Industry
- ABLV
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABLV
- QNCX Health Care
- Exchange
- ABLV Nasdaq
- QNCX Nasdaq
- Market Cap
- ABLV 50.9M
- QNCX 47.7M
- IPO Year
- ABLV N/A
- QNCX 2019
- Fundamental
- Price
- ABLV $1.00
- QNCX $1.55
- Analyst Decision
- ABLV
- QNCX Strong Buy
- Analyst Count
- ABLV 0
- QNCX 5
- Target Price
- ABLV N/A
- QNCX $8.00
- AVG Volume (30 Days)
- ABLV 9.3K
- QNCX 344.4K
- Earning Date
- ABLV 04-23-2025
- QNCX 08-12-2025
- Dividend Yield
- ABLV N/A
- QNCX N/A
- EPS Growth
- ABLV N/A
- QNCX N/A
- EPS
- ABLV N/A
- QNCX N/A
- Revenue
- ABLV $128,932,647.00
- QNCX N/A
- Revenue This Year
- ABLV N/A
- QNCX N/A
- Revenue Next Year
- ABLV N/A
- QNCX N/A
- P/E Ratio
- ABLV N/A
- QNCX N/A
- Revenue Growth
- ABLV N/A
- QNCX N/A
- 52 Week Low
- ABLV $0.55
- QNCX $0.51
- 52 Week High
- ABLV $1.90
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- ABLV 41.18
- QNCX 61.13
- Support Level
- ABLV $1.02
- QNCX $1.48
- Resistance Level
- ABLV $1.13
- QNCX $1.68
- Average True Range (ATR)
- ABLV 0.07
- QNCX 0.14
- MACD
- ABLV -0.01
- QNCX 0.01
- Stochastic Oscillator
- ABLV 23.96
- QNCX 73.47
About ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.